Medical Disclaimer: Educational Content Only

Bromantane & ADHD: A UK Evidence-Based Review

An in-depth analysis of bromantane as an atypical Russian nootropic — examining mechanism, clinical evidence, safety profile, and regulatory status for UK readers.

Quick Answer

Bromantane is not an approved ADHD treatment in the UK and there are no published randomised controlled trials testing it in diagnosed ADHD. However, its unusual mechanism — upregulating dopamine synthesis via gene expression rather than blocking dopamine reuptake — has made it a topic of growing interest among adults who tolerate stimulants poorly or who have been affected by the UK's ongoing ADHD medication shortage.

What Is Bromantane? Mechanism Clinical Evidence Safety UK Legal Status
KEY POINTS

Key Takeaways

No Direct ADHD Trials

Clinical evidence for bromantane is concentrated on asthenia — not ADHD.

Novel Mechanism

Upregulates TH and AAAD gene expression — 2–2.5x increase in rat hypothalamus.

Not MHRA-Licensed

No UK medicines authorisation — grey area as unscheduled research chemical.

WADA-Banned Since 1997

Category S6.A stimulant — prohibited in-competition with no minimum threshold.

11.2hr Half-Life

Once-daily dosing with 8–12 hour duration of effects.

Favourable Safety Profile

Only 3% reported side effects in 728-patient trial — but long-term data absent.

NICE first-line for ADHD remains methylphenidate (children) and methylphenidate or lisdexamfetamine (adults) under NG87. NHS England estimates ~2.5 million people in England likely have ADHD.

CONTENTS

Table of Contents

1 What Is Bromantane? 2 ADHD in the UK 3 How Bromantane Works 4 Clinical Evidence 5 vs Conventional Medications 6 Dosing & Protocols 7 Safety & Side Effects 8 UK Legal Status 9 Can It Replace ADHD Meds? 10 Who Might Consider It? 11 Stacks & Combinations 12 Sourcing in the UK
FAQ Conclusion
1

What Is Bromantane?

The compound and its origins

Bromantane is the common name for N-(4-bromophenyl)adamantan-2-amine — a synthetic adamantane derivative chemically related to the antiviral and Parkinson's drugs amantadine and memantine. It was developed in the 1980s at the Zakusov State Institute of Pharmacology of the USSR Academy of Medical Sciences in Moscow.

Originally designed for Soviet military and cosmonaut use, bromantane was intended as a compound that could maintain alertness and physical performance under heat, hypoxia and emotional stress — without the cardiovascular cost of amphetamines. Explore our comprehensive guide to modafinil and alternatives for similar wakefulness support.

Actoprotector Classification

Russian pharmacology classifies bromantane as an "actoprotector" — a synthetic adaptogen that enhances work capacity without increasing oxygen consumption. It is the only adamantane-class actoprotector currently approved as a medicine.

Russia licensed it around 2009 under the brand name Ladasten for the treatment of asthenia — a condition of mental and physical fatigue often accompanied by mild anxiety, broadly comparable to medically unexplained chronic fatigue states in Western nosology.

Not MHRA, FDA, or EMA Approved

Bromantane is not authorised by any Western regulatory body for any medical indication.

Quick Facts

Chemical Name

N-(4-bromophenyl)adamantan-2-amine

Developed

1980s, Zakusov Institute, Moscow

Russian Brand Name

Ladasten (approved 2009)

Class

Actoprotector / Atypical stimulant

The 1996 Atlanta Olympics Scandal

Bromantane's global notoriety dates from the 1996 Summer Olympics, when five athletes (four Russian, one Lithuanian) tested positive. The IOC initially stripped two Russian bronze medallists, but the Court of Arbitration for Sport overturned the disqualifications because bromantane was not explicitly listed on the banned schedule at the time.

It was added to the prohibited list in 1997 and remains on the WADA Prohibited List under category S6.A (Non-Specified Stimulants), prohibited in-competition with no minimum threshold.

2

ADHD in the UK: Clinical Context

Understanding the landscape

NHS hospital entrance sign showing the National Health Service branding
NHS England

Attention-Deficit/Hyperactivity Disorder (ADHD) is a neurodevelopmental condition characterised by persistent inattention, hyperactivity and impulsivity that impairs academic, occupational or social functioning beyond what is expected for age.

UK Prevalence (NICE Estimates)

3-4%

of adults

5%

of children

NHS England estimates ~2.5 million people in England likely have ADHD.

Rising Diagnosis Rates

OpenSAFELY analysis (Nov 2025): 1.6% of males and 0.9% of females had recorded ADHD diagnosis in 2024/25, up from 0.7% and 0.2% in 2016/17.

NICE First-Line Treatments (NG87)

Stimulants

  • • Methylphenidate (Ritalin, Concerta XL, Equasym XL, Medikinet XL)
  • • Lisdexamfetamine (Elvanse / Elvanse Adult)
  • • Dexamfetamine (second-line)

First-line: children → methylphenidate; adults → methylphenidate or lisdexamfetamine

Non-Stimulants

  • • Atomoxetine (Strattera)
  • • Guanfacine (Intuniv)

Typically third- or fourth-line options

Why Patients Seek Alternatives

UK Supply Shortages

National Patient Safety Alerts since September 2023 covering methylphenidate, lisdexamfetamine, dexamfetamine and atomoxetine. NELFT advised pausing new patient initiations.

Controlled Drug Status

Methylphenidate and lisdexamfetamine are Schedule 2 CDs, limiting private prescribing and complicating international travel.

Stimulant Intolerance

Anxiety, insomnia, appetite suppression, tachycardia or rebound — particularly with comorbid generalised anxiety disorder. Explore natural alternatives for anxiety.

Long NHS Waiting Lists

ADHD Taskforce data (2024): 40% of patients reported waiting two years or more for an assessment.

3

How Bromantane Works

The science behind its mechanism

A hand in a glove supports a glowing blue brain with abstract connections in a dark background representing neuroscience and cognitive enhancement

Indirect, Genomic Dopamine Enhancement

Unlike amphetamines and methylphenidate that act on the dopamine transporter (DAT), bromantane works upstream through gene expression.

Russian research led by Yu. V. Vakhitova and colleagues (Russian Academy of Sciences, 2004–2012) demonstrated that bromantane induces transcriptional upregulation of key enzymes. For context, learn more about how the brain produces neurotransmitters.

Tyrosine Hydroxylase (TH)

The rate-limiting enzyme converting L-tyrosine to L-DOPA

2-2.5× increase in rat hypothalamus

AAAD

Aromatic L-amino acid decarboxylase — converts L-DOPA to dopamine

Co-induced with TH expression

Effects span the hypothalamus, striatum, ventral tegmental area, nucleus accumbens and substantia nigra — anatomically the same dopaminergic pathways implicated in ADHD's reward/motivation/attention circuits.

Epigenetic Regulation

Associated with cytosine demethylation in the TH gene promoter in hypothalamic neurons (Seredenin et al., Genetika, 2006) — implying direct epigenetic modulation.

Onset Timeline

1

1.5–2 hours

Peak enzyme induction

2

1–3 days

Full compound effect emerges

3

Days 7–14

Compound benefits accumulate

4

8–12 hours

Duration of acute effect

~11.2 hours

Human Half-Life

Additional Neurochemical Effects

Serotonin

Weak SERT inhibition

GABA

Potentiates GABA-A receptors

Noradrenaline

Modest elevation

Neurotrophins

↑ BDNF and NGF expression

Why This Matters for ADHD

No tolerance from receptor downregulation — bromantane does not flood synapses with neurotransmitter

Anxiolytic rather than anxiogenic — relevant for adults with comorbid GAD or social anxiety

These are theoretical advantages; they have not been tested head-to-head against methylphenidate or lisdexamfetamine in any ADHD population.

Source: 2024 Frontiers in Psychiatry review (Cervetto et al.) on dopamine involvement in ADHD

4

Clinical Evidence

What the research actually says

The Honest Summary

There is no direct evidence. A PubMed search yields no randomised controlled trials, observational studies or even case series of bromantane in patients with a formal ADHD diagnosis. The clinical evidence must be extrapolated from adjacent indications.

The 728-Patient Asthenia Trial

Russia, Multicentre, 2011 (PMID 21322821)

728

Patients

28

Clinical Centres

76%

CGI-S Response

90.8%

CGI-I Response

Trial Parameters

  • Indication: Psychoautonomic syndrome with asthenic disorders
  • Dose: 50–100 mg ladasten once daily
  • Duration: 28 days
  • Onset: Anti-asthenic effect visible by day 3

Safety Results

  • Side effects: ~3% of patients
  • Discontinuation: 0.8%
  • Serious AEs: None reported
  • Post-withdrawal: Benefits persisted 1 month after stopping

Important: Symptoms improved across anxiety–depressive spectrum disorders, autonomic dystonia and sleep disorders — domains that overlap with daily functional difficulties many adults with ADHD report. But asthenia is not ADHD.

Healthy Volunteer Cognition Studies

EEG/Psychophysiology Study (Vyatleva et al., 2000)

10 healthy male volunteers, single oral dose

Key Findings:
  • • No subjective change in untired men
  • • EEG signatures of "moderate vigilance rise" (↑ mid-frequency alpha; ↓ delta and beta1 power)
  • • Improved range and stability of attention, reaction time, operator performance

Sleep-Deprived Volunteer Studies

Single 100 mg dose:

  • • Sharpened attention
  • • Reduced reaction-time errors
  • • Lowered self-rated anxiety
  • • No blood pressure elevation

Caveat: These are interesting signals but the studies are small, mostly Russian-language, and lack modern methodological rigour (placebo control quality, blinding, registered protocols).

What This Means

Anyone telling you bromantane is "clinically proven for ADHD" is misrepresenting the evidence. What can be said:

✓

The mechanism is plausible

✓

The asthenia evidence is consistent with improvements in attention, energy and anxiety domains relevant to adult ADHD

✗

High-quality Western RCTs in ADHD populations do not exist

5

Bromantane vs Conventional ADHD Medications

A side-by-side comparison

Parameter Bromantane Methylphenidate Lisdexamfetamine Atomoxetine
Drug Class Atypical stimulant / actoprotector CNS stimulant Prodrug amphetamine Selective NRI
Primary Mechanism Upregulates TH/AAAD gene expression; weak DAT/SERT inhibition DAT inhibitor; NET inhibitor Released d-amphetamine; releases & blocks reuptake of DA/NE Selective noradrenaline reuptake inhibitor
Onset of Acute Effect 1.5–2 hours; full effect over 1–3 days 30–60 min (IR); 1–2 hr (MR) 1–2 hours 2–4 weeks for full effect
Half-life (Humans) ~11.2 hours 2–4 hr (IR); 8–12 hr (MR) ~10–13 hr ~5 hr
Anxiety Profile Anxiolytic May worsen May worsen Neutral/may improve
Abuse Potential Low Moderate–high (Sch 2 CD) Moderate (Sch 2 CD) Low
Tolerance / Withdrawal Not reported Some tolerance; rebound common Possible; rebound common Minimal
UK Legal Status Unlicensed; not scheduled Class B / Sch 2 CD Class B / Sch 2 CD POM, not CD
WADA Status BANNED Banned in-competition Banned in-competition Not banned

Theoretical Advantages

  • No euphoria, low diversion risk — not a controlled substance, no street value, no classical reinforcement in animal studies
  • No documented withdrawal — 728-patient trial showed effects persisting one month after stopping
  • Anxiolytic — meaningful advantage for adults with ADHD + comorbid GAD or social anxiety
  • Once-daily dosing — long half-life and absence of "afternoon crash"

Real Disadvantages

  • Not licensed — no regulatory body outside Russia has approved bromantane for any condition
  • Narrow evidence base — largely Russian-language with limited Western replication
  • Unknown long-term safety — longest published continuous-dosing study is 28 days
  • CYP enzyme induction — may reduce levels of CYP3A4 substrates including SSRIs, benzodiazepines, oral contraceptives
  • Sourcing risk — no licensed UK supplier
6

Dosing & Protocols

Educational reference — not medical advice

The following figures are reported from Russian clinical literature and online community accounts. They are not a recommendation and should not be construed as personal medical advice.

Typical Dose

50–100 mg

Once daily in the morning

Onset

1.5–2 hrs

Subjective effects begin

Duration

8–12 hrs

Of acute effect

Effect Build-Up Timeline

1

Hours 1.5–2

Acute phase

Subjective effects appear; peak enzyme induction in hypothalamus

2

Day 3

Clinical effect

Physician-rated anti-asthenic effect visible in trials

3

Days 7–14

Peak accumulation

Full benefit accumulates as gene-expression changes compound

4

1 Month Post-Withdrawal

Persistence

Therapeutic benefit maintained in 728-patient trial — no documented withdrawal

Cycling Protocols

Russian protocols use 28-day courses with weeks-to-months off. Nootropic communities report:

  • 4 weeks on / 2–4 weeks off
  • 8 weeks on / 2–3 weeks off

Note: The pharmacological rationale for cycling is precautionary rather than evidence-based.

Sex Differences

Women

Tmax ~2.75 hrs

Men

Tmax ~4 hrs

Women may perceive onset sooner due to faster absorption

No Validated ADHD Dosing Protocol

There is no validated dosing protocol for ADHD because no trial has been conducted in an ADHD population. All dosing information is extrapolated from asthenia trials and community reports.

7

Safety Profile & Side Effects

Understanding the risks

3%

Reported any adverse event

0.8%

Discontinued due to side effects

0

Serious adverse events reported

28

Days max continuous study

Source: 728-patient multicentre Russian asthenia trial (PMID 21322821)

Commonly Reported Side Effects

Mild Insomnia

Late-day dosing risk

Headache

Mild and transient

GI Upset

Nausea rare

Irritability

Uncommon

Dry Mouth

Occasional

Drug Interactions to Know About

!

CYP-450 Induction — Critical

May lower plasma levels of CYP3A4 substrates including SSRIs, benzodiazepines, oral contraceptives and certain antiepileptics. Contraceptive failure is a credible theoretical risk.

!

MAOIs — Strongly Contraindicated

Combination is strongly contraindicated due to potential serotonergic/dopaminergic crisis.

Other Dopaminergics

Theoretical additive effects with stimulants, bupropion or selegiline. Co-administration with prescribed ADHD stimulants has no safety data.

SSRIs / SNRIs

Theoretical serotonergic burden plus CYP interactions — medical guidance essential.

Contraindications & Special Populations

Pregnancy & Breastfeeding

Avoid. Animal studies suggest dose-dependent effects on offspring neurodevelopment. No adequate human pregnancy data.

Children & Adolescents

Not recommended. Paediatric ADHD requires specialist diagnosis. No paediatric safety data exist.

Cardiovascular Disease

Avoid without clinician input. Any compound altering catecholamine signalling warrants caution in arrhythmia or structural heart disease.

Severe Hepatic Impairment

Theoretical concern due to hepatic metabolism.

History of Substance Misuse

While bromantane has low abuse potential, addiction history requires specialist input.

Hormonal Contraception Users

Use backup contraception due to CYP3A4 induction — theoretical risk of contraceptive failure.

Long-Term Safety: The Largest Evidence Gap

The longest published continuous-dosing study in humans is 28 days. The frequently quoted observation that benefits persist for ~1 month after stopping has been used to argue against long-term continuous dosing.

There are no multi-year safety data of the type that exist for methylphenidate and lisdexamfetamine.

9

Can Bromantane Replace ADHD Medication?

The short answer

No.

Bromantane cannot and should not replace prescribed ADHD medication. The reasons are unambiguous.

No ADHD Trial Evidence

Substituting an unproven compound for evidence-based treatment is a downgrade of care.

Regulatory & Quality Gaps

Licensed ADHD medication is manufactured to GMP standards with known dosing. Research-chemical bromantane is not.

No Specialist Oversight

NICE NG87 includes baseline cardiovascular screening, growth monitoring (children), and structured titration. Self-medication has none of this.

Shortage ≠ Solution

Switching from a licensed medicine because of supply problems does not solve the underlying clinical issue.

The Only Reasonable Framing

The only reasonable framing of bromantane in an ADHD context is as a topic of informed discussion with your prescriber — for example, for adults who genuinely cannot tolerate any licensed agent — and that discussion will, in nearly every case, point back toward established alternatives such as guanfacine or atomoxetine before unlicensed compounds.

Established alternatives to explore first: Guanfacine → Atomoxetine → then, only if exhausted, bromantane with specialist input

10

Who Might Reasonably Consider Bromantane?

With healthcare-provider input

May Consider

Adults with subclinical attention or fatigue symptoms

Do not meet full ADHD criteria but seek cognitive support

Adults who experience marked anxiety, palpitations or insomnia on stimulants (see ashwagandha for stress support)

Have already explored licensed non-stimulant options

People seeking a non-controlled, non-euphoric daytime energy/focus aid

No abuse potential, no street value

Adults with chronic-fatigue-spectrum complaints

Where Russian asthenia evidence is most directly applicable

NOT Appropriate For

Children or adolescents with suspected or confirmed ADHD

Always specialist-led care required

Pregnant or breastfeeding women

No safety data exist

Those with significant cardiovascular disease, uncontrolled hypertension or arrhythmia

Warrants specialist input

Anyone taking MAOIs, or SSRIs/SNRIs without medical guidance

Interaction risk

Competitive athletes subject to anti-doping testing

WADA-banned; no threshold

Anyone using hormonal contraception without a back-up method

CYP induction risk — contraceptive failure theoretical risk

11

Stacks, Combinations & the Polypharmacy Problem

Proceed with caution

Bromantane is commonly discussed within nootropic communities as a "foundation" for dopaminergic stacks because it builds biosynthetic capacity rather than depleting it.

Common Pairings (Community Reports)

L-Tyrosine (500–1000 mg)

The substrate that TH converts to L-DOPA

"More enzyme + more substrate = more dopamine"

Limited ADHD RCT support

Rhodiola rosea

Botanical adaptogen with modest evidence for fatigue and mild attention complaints

Widely available, benign safety profile

Choline Sources

CDP-choline, alpha-GPC

Pragmatically paired to balance cholinergic transmission

Racetams

Piracetam, phenylpiracetam, noopept

Frequently combined in Russian-derived "smart drug" stacks

Phenylpiracetam is WADA-banned

A Serious Caution

Stacking unlicensed compounds amplifies the unknown-interaction risk. None of these combinations has been tested in ADHD.

The more compounds added, the harder it becomes to attribute either benefit or harm — and the harder it is for any future clinician to manage an adverse event.

12

Sourcing Quality Bromantane in the UK

The single most under-appreciated risk factor

Grey-market vendors vary enormously. If you choose to research bromantane, sourcing quality is critical.

Red Flags to Avoid

No third-party Certificate of Analysis (CoA) with HPLC purity ≥98%

Vague or vanity branding without batch numbers

Therapeutic claims about ADHD, depression or any disease

No physical UK or EU address

Prices dramatically below market norm

No clarity on dosing form, weight per capsule or excipients

Quality Markers

Independent HPLC purity testing by a recognised laboratory

Batch-specific CoAs available for inspection

"Research / laboratory use only" labelling (legally appropriate)

Clear, conservative information without therapeutic claims

Key Point

A reputable supplier will direct you toward your GP for clinical advice, not away from one.

Three white canisters of bromantane powder displayed in a group arrangement with red caps
Premium Quality
Research-Grade Bromantane

Ready to Source Quality Bromantane?

Third-party tested for purity. HPLC verified ≥98%. Fast UK shipping available.

HPLC Verified
Batch CoA Available
No Fillers
View Product

Affiliate link. We may earn a commission at no extra cost to you.

FAQ

Frequently Asked Questions

CONCLUSION

The Bottom Line

Bromantane is one of the most pharmacologically interesting compounds in the broader nootropic landscape. Its capacity to upregulate dopamine synthesis through gene expression — rather than ransacking existing synaptic pools — is mechanistically attractive in a condition like ADHD, where dopaminergic dysfunction is central and stimulant tolerance, anxiety and dependence concerns are real clinical headaches.

But mechanism alone is not evidence. There is no published clinical trial of bromantane in ADHD. The strongest human data — the 728-patient Russian asthenia trial — supports its safety and antiasthenic effect, not its efficacy in a neurodevelopmental disorder with strict diagnostic criteria.

The Right Framing for UK Readers

If you suspect you have ADHD

Pursue formal assessment via your GP, NHS ADHD service, or registered private psychiatrist.

If you have ADHD and struggle with stimulants

Discuss switching options with your psychiatrist — not research-chemical suppliers.

If you're an athlete subject to testing

Bromantane is off-limits, full stop.

If you're a healthy adult interested in cognitive support

Approach bromantane as experimental; source carefully; dose conservatively; discuss with a medical professional.

"Bromantane is genuinely intriguing. It is not a substitute for properly diagnosed and treated ADHD."

Understand the difference, and you understand the most important thing in this entire article.

ACTIONABLE

Recommendations

A staged approach based on your situation

1

Before Considering Bromantane at All

Essential first steps

A

If ADHD is suspected, pursue formal assessment via your GP, an NHS ADHD service, or a registered private psychiatrist. NHS England's Right to Choose pathway can shorten waiting times.

B

Optimise the basics: sleep, exercise, structured routine, and CBT-based ADHD coaching where appropriate.

2

If You Have a Diagnosis and Are Exploring Options

Work through established pathways

A

Work through NICE-recommended first-line (methylphenidate / lisdexamfetamine) and second-line (atomoxetine, guanfacine) options under specialist supervision.

B

Track symptoms with validated tools (ASRS-v1.1, Conners' Adult ADHD Rating Scale) to inform decisions.

3

Only If Licensed Options Are Exhausted

With prescriber input only

A

Discuss any off-label or unlicensed adjunct (including bromantane) explicitly with your psychiatrist.

B

If proceeding, source from a vendor providing third-party HPLC CoAs.

C

Start at 50 mg daily in the morning, monitor blood pressure, sleep and anxiety; do not exceed published trial doses (≤100 mg/day).

D

Avoid co-administration with MAOIs; flag interactions with hormonal contraceptives and CYP3A4 substrates.

Thresholds That Should Change Your Decision

New chest pain, palpitations, significant blood pressure rise → stop and seek medical review

Worsened mood, sleep collapse, or escalating anxiety → stop and seek medical review

Inability to verify product purity / supplier credibility → do not proceed

A formal ADHD diagnosis is made → return to NICE-recommended pathways with your specialist

Caveats & Limitations

  • 1

    The clinical evidence base for bromantane is dominated by Russian-language literature with variable methodological transparency. Findings should be regarded as suggestive rather than definitive.

  • 2

    Half-life, bioavailability and metabolism figures cited here come predominantly from a small number of pharmacokinetic studies and may not generalise across populations.

  • 3

    The 728-patient Russian asthenia trial is repeatedly cited across academic and commercial sources; readers should be aware that some online discussion conflates asthenia data with claims about ADHD, depression and cognitive enhancement that the original study does not directly support.

  • 4

    UK ADHD prevalence figures (3–4% adults, 5% children) are NICE estimates applied to population data, not direct epidemiological counts; recorded diagnosis rates are substantially lower.

  • 5

    The UK ADHD medication shortage status is dynamic; DHSC and the NHS Specialist Pharmacy Service publish the most current information. Statements here reflect the position as of mid-2025/early 2026.

Medical Disclaimer: This article is educational. Nothing here constitutes a recommendation to use, purchase or consume bromantane in place of, or in addition to, prescribed treatment. Always consult a qualified UK healthcare professional.